Quantum-Si (QSI) AI Stock Analysis

• Market Cap: $348.94M
• Dividend Yield: N/A
• Average Volume (3M): 7.97M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.74
• Revenue Growth: 167.94%
• EPS Growth: -3.66%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 181,760,620
• 10 Day Avg. Volume: 7,874,750
• 30 Day Avg. Volume: 7,965,841
• PEG Ratio: 0.18
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.52
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: 17.95
• Enterprise Value/Gross Profit: 103.45
• Enterprise Value/Ebitda: -0.49
• 1Y Price Target: $3.75
• Price Target Upside: 116.76% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 55 Neutral
• Price Target: $2.00 ▲(15.61%Upside)

Quantum-Si receives a moderate score driven by its significant revenue growth and strong technical outlook, countered by ongoing profitability and cash flow challenges. The valuation remains a concern due to negative earnings, but positive sentiment from corporate events and strategic advancements provide stability and potential for future growth.

Positive Factors

International Growth

The company reported that ex-US revenues made up nearly 85% of the total revenues, indicating strong international growth potential.

Partnership Impact

The recent partnership with Avantor is expected to provide support to grow sales in the biopharma sector.

Negative Factors

Financial Performance

The company reported total revenues of $808K, lower than consensus estimated revenue of $960K.

Funding Uncertainty

Uncertainty regarding NIH funding could continue to impact the academic research market.

Quantum-Si Business Overview & Revenue Model

Company Description

Quantum-Si (QSI) is a biotechnology company focused on revolutionizing the field of proteomics through the development of next-generation protein sequencing technology. The company's core product is the Platinum™ platform, which aims to simplify and accelerate the analysis of proteins. By providing a more comprehensive understanding of proteins, Quantum-Si seeks to advance the discovery and development of new biomarkers and therapeutics, ultimately enhancing personalized medicine approaches.

How the Company Makes Money

Quantum-Si generates revenue primarily through the sale and deployment of its Platinum™ platform, which includes hardware, software, and consumables used for protein sequencing. The company also offers related services, such as data analysis and interpretation, which provide additional revenue streams. Quantum-Si's revenue model may include direct sales to research institutions, pharmaceutical companies, and clinical laboratories. Additionally, partnerships or collaborations with academic institutions and industry leaders may contribute to its earnings by expanding its market reach and driving adoption of its technology.

Quantum-Si Financial Statement Overview

Summary

Quantum-Si exhibits strong revenue growth but faces significant profitability challenges with negative margins and net losses. The balance sheet is robust with low leverage, yet cash flow remains a concern, reflecting ongoing operational challenges.

Income Statement

The company has shown strong revenue growth from $1.08 million in 2023 to $3.06 million in 2024, a significant improvement. However, gross profit margin is low at 52.33%, and the company is still operating at a substantial net loss of $101 million, resulting in a negative net profit margin of -3303.83%. EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges.

Balance Sheet

Quantum-Si maintains a strong equity position with a debt-to-equity ratio of 0.06, indicating low financial leverage. The equity ratio is high at 86.89%, suggesting a strong balance sheet. However, the company still reports significant net losses, impacting return on equity, which is negative at -46.89%. This indicates inefficiencies in using equity to generate profit.

Cash Flow

Operating cash flow is negative at -$87.8 million, reflecting ongoing operational cash strains. There has been a slight improvement in free cash flow over the years, but it remains negative at -$92.4 million. The operating cash flow to net income ratio is 0.87, showing that cash flow is closely tracking net income losses, which is a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.44M	3.06M	1.08M	0.00	0.00	0.00
Gross Profit	1.82M	1.60M	488.00K	-2.58M	-1.04M	-894.00K
EBITDA	-106.79M	-103.98M	-91.80M	-129.86M	-95.87M	-35.80M
Net Income	-100.72M	-101.01M	-95.96M	-141.04M	-88.95M	-36.61M
Balance Sheet
Total Assets	271.22M	247.87M	298.25M	391.49M	503.23M	40.59M
Cash, Cash Equivalents and Short-Term Investments	232.60M	209.60M	257.74M	351.31M	471.30M	36.91M
Total Debt	12.05M	12.95M	15.30M	17.45M	8.08M	1.75M
Total Liabilities	24.30M	32.45M	26.63M	32.78M	26.19M	4.50M
Stockholders Equity	246.92M	215.42M	271.62M	358.71M	477.03M	36.09M
Cash Flow
Free Cash Flow	-95.53M	-92.38M	-99.31M	-101.30M	-72.58M	-33.03M
Operating Cash Flow	-90.74M	-87.80M	-94.04M	-90.56M	-66.81M	-32.57M
Investing Cash Flow	-9.42M	-32.67M	143.43M	137.19M	-450.94M	-461.00K
Financing Cash Flow	84.31M	35.88M	149.00K	1.91M	516.63M	37.01M

Quantum-Si Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.73
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QSI, the sentiment is Positive. The current price of 1.73 is below the 20-day moving average (MA) of 1.84, above the 50-day MA of 1.68, and above the 200-day MA of 1.51, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 46.93 is Neutral, neither overbought nor oversold. The STOCH value of 9.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QSI.

Quantum-Si Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$373.36M	―	-41.31%	―	―	-7.93%
QSI	55 Neutral	$348.94M	―	-40.23%	―	167.94%	-3.66%
SEER	55 Neutral	$124.17M	―	-24.73%	―	-1.02%	-8.59%
FHTX	54 Neutral	$301.00M	―	322.49%	―	-30.66%	36.48%
Sector *	52 Neutral	$7.52B	0.21	-63.76%	2.30%	16.15%	0.89%
AVIR	47 Neutral	$314.08M	―	-30.47%	―	―	-22.66%
NAUT	41 Neutral	$98.59M	―	-30.93%	―	―	-1.20%

Quantum-Si Corporate Events

Quantum-Si Announces $50M Securities Purchase Agreement

On July 3, 2025, Quantum-Si Incorporated announced a securities purchase agreement with an institutional investor for a registered direct offering of 29,940,119 shares of common stock, expected to generate approximately $50 million in gross proceeds. The company plans to use the funds for product development, commercialization, and general corporate purposes, with the offering expected to close on July 8, 2025, subject to customary conditions.

The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.

Quantum-Si Shareholders Approve Key Proposals at Annual Meeting

On May 16, 2025, Quantum-Si held its Annual Meeting where shareholders voted on three key proposals. The meeting saw the reelection of board members, the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2025, and the approval of executive compensation, reflecting strong shareholder support for the company’s governance and financial strategies.

The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.